Resideo to Release First Quarter 2021 Financial Results on May 6, 2021
Get Alerts REZI Hot Sheet
Join SI Premium – FREE
AUSTIN, Texas, April 15, 2021 /PRNewswire/ -- Resideo Technologies, Inc. (NYSE: REZI) will release first quarter 2021 financial results after the close of the New York Stock Exchange on Thursday, May 6, 2021. A conference call and simultaneous webcast to discuss the results will be held on Thursday, May 6 at 5:00 p.m. EDT.
Conference Call and Webcast Details
Resideo will hold a conference call with investors on May 6, 2021, at 5:00 p.m. EDT. A real-time audio webcast of the call will be accessible at https://investor.resideo.com, where related materials will be posted before the call. A replay of the webcast will be available following the presentation.
To join the conference call, please dial 833-972-2949 (U.S., toll-free) or 1-236-714-2869 (international), with the conference title "Resideo First Quarter 2021 Earnings" or the conference ID: 9843267.
About Resideo
Resideo is a leading global manufacturer and distributor of technology-driven products and solutions that provide comfort, security, energy efficiency and control to customers worldwide. Building on a 130-year heritage, Resideo has a presence in more than 150 million homes, with 15 million systems installed in homes each year. We continue to serve more than 110,000 professionals through leading distributors, including our ADI Global Distribution business, which exports to more than 100 countries from more than 200 stocking locations around the world. For more information about Resideo, please visit www.resideo.com.
Contacts: | |
Investors: | Media: |
Jason Willey | Oliver Clark |
View original content to download multimedia:http://www.prnewswire.com/news-releases/resideo-to-release-first-quarter-2021-financial-results-on-may-6-2021-301270204.html
SOURCE Resideo Technologies, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
- From Factory to Site: The Direct Approach Transforming Construction
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!